Guidelines for preparing the abstract
- SaMED is welcoming research from all (bio)medical fields.
- Abstract must contain original material.
- Only abstracts in the English language will be reviewed.
- All abstracts will be reviewed by Scientific Board.
- Authors have to choose their presentation preferences: oral presentation or poster presentation. Scientific Board withholds the right to change presentation preference if it is needed.
- All participants might be asked to change some parts of their abstracts in order for their abstracts to be accepted. Therefore we kindly ask all participants to check their emails on the regular basis.
- All participants will be contacted in the period from 1th to 30th of December 2018, if minor changes to abstracts are needed.
- By 30th of December 2018. all participants will be contacted by Scientific Board with the final decision about abstract acception.
- Any applicant for active participation has the right to become a passive participant if his abstract is rejected by our Scientific Board.
- Late submissions will not be accepted.
* IMPORTANT -
After abstract is approved, active participant will be contacted by Financial Team with detailed instructions for participation fee payment. Participants are required to pay registration fees by the indicated deadlines in order for their abstracts to be put on the congress schedule and published in the SaMED 2019 Abstract Book. We are not going to be able to publish abstract if participation fees are not covered until the late registration deadline. Participation fees payment deadlines are available at this link.
- The abstract should not exceed 300 words (including Background, Methods, Results and Conclusion).
- The title must be short, clearly indicating the objective of the research. Only first letter of each word in the title should be capital. Do not include any abbreviations or commercial names of the drugs.
- Full name of the first author should be written in CAPITAL LETTERS, and the name of co-author(s) in lower-case letters. Also, write the full address for correspondence.
- Generic names should be used the first time a drug is mentioned and the proprietary name should be in brackets.
- It is not permitted to include tables, charts or pictures in your abstract.
- At the end of the abstract, please write 3 to 5 keywords that best describe your research.
- Include references after the abstract.
YOUR ABSTRACT SHOULD CONTAIN THE FOLLOWING PARTS:
- AUTHORS AND FULL ADDRESS FOR CORRESPONDENCE:
- BACKGROUND: Describe the current state of scientific progress regarding your field.
- METHODS: Describe which methods and materials did you use to conduct your research.
- RESULTS: Write only the most important results of your research.
- CONCLUSION: Interpret the meaning of the results.
- KEYWORDS: Write 3 to 5 keywords that best describe your research.
- REFERENCES: Vancouver style.
DOWNLOAD TEMPLATE FOR ABSTRACTS
The Effects of Lead and Selenium on Melanoma Induction
ISABEL SÁ1*, Tânia Nogueira2, Elisabete Cunha1
1University of Vigo, Spain
2Faculty of Medicine University of Porto, Portugal.
Address: Lagoas s/n,
Background: Melanoma is a malignant skin cancer and is one of the most aggressive malignancies in humans. Heavy metals, including lead, are known to cause cellular toxicity and have been studied for their potentials to induce apoptosis in tumor cells. Since selenium is considered to act protectively in cases of lead poisoning, this study focused on the effects of sodium selenite and lead chloride, both alone and combined, on melanoma cell apoptosis.
Methods: This study was carried out by doing cell culture of melanoma cells (B16-F10 cell line) and using C57BL/6 mice. Melanoma cells suspended in lead (II) chloride, sodium selenite,or lead (II) chloride+ sodium selenite solutions were injected subcutaneously to mice to induce tumor growth. After 12 days, tumors were excised and measured, followed by flow cytometry and a statistical analysis using a one-way ANOVA.
Results: In the group of mice receiving a single injection of melanoma cells suspended in 10 µmol/l of lead (II) chloride, the growth of tumor was significantly slower than in the control group. In mice treated with lead (II) chloride 50 µmol/l and 100 µmol/l, no tumor was visible at the end of the experiment. With a single injection of lead (II) chloride and sodium selenite at concentrations ≥10 µmol/l, the weight and size of the tumor were substantially smaller than in the control group.
Conclusion: The effect of lead (II) chloride on melanoma induction is dependent on the concentration of lead (II) chloride. Future applications may include the use of lead (II) chloride to increase apoptosis and necrosis in tumor cells and thus suppress tumor cells proliferation.
Keywords: Selenium; Lead; Melanoma; Apoptosis; Necrosis
How to prepare the presentation?
We have provided guidelines for both oral and poster presentations.